PURPOSE Standard first-line therapy for EGFR-mutant advanced non–small-cell lung
cancer (NSCLC) is an epidermal growth factor receptor (EGFR)–directed oral tyrosine …

Abstract Background The Japan Guidelines of Lung Cancer Therapy recommend epidermal
growth factor receptor-tyrosine kinase inhibitors as a first-line therapy for advanced/recurrent …

Introduction The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs)
gefitinib and erlotinib are gaining an increasing role in the management of advanced non …

Introduction Although standard schedule of gefitinib was the administration of 250 mg tablet
every day, many patients need dose reduction because of toxicities. However, the efficacy of …

ABSTRACT EGFR-TKI therapy produces a dramatic clinical response in patients with
NSCLC harboring EGFR mutation. However, clinical outcomes should be improved further …

Introduction: In non–small-cell lung cancer, an exon 19 deletion and an L858R point
mutation in the epidermal growth factor receptor (EGFR) are predictors of a response to …

Purpose Preclinical studies indicate that gefitinib (Iressa, ZD1839; AstraZeneca, Wilmington,
DE), an orally active epidermal growth factor receptor tyrosine kinase inhibitor, may enhance …

Purpose This phase III study (V-15-32) compared gefitinib (250 mg/d) with docetaxel (60
mg/m2) in patients (N= 489) with advanced/metastatic non–small-cell lung cancer (NSCLC) …

Abstract On July 13, 2015, the FDA approved gefitinib (Iressa; AstraZeneca UK Limited) for
the treatment of patients with metastatic non–small cell lung cancer (NSCLC) whose tumors …

7513 Background: Early clinical studies with gefitinib (G) showed promising efficacy and
mild toxicity in patients (pts) with advanced NSCLC. Thus, G was an ideal agent to evaluate …